Evaluating the evaluators - Developing evidence of quality oversight effectiveness for clinical trial monitoring:...

Area of Science:

• Clinical research methodology
• Regulatory science
• Pharmaceutical development

Background:

• Clinical trial quality details are rarely published, creating significant challenges for physicians, advisory groups, and regulators.
• The effectiveness of current methods for detecting critical errors that compromise trial integrity remains untested.
• Source Data Verification (SDV), a long-standing oversight method, lacks evidence of effectiveness and shows significant evidence of ineffectiveness.

Purpose of the Study:

• To address the gaps in clinical trial monitoring, oversight cost, and test validation and effectiveness by analyzing regulatory documents.
• To propose a framework for evaluating and improving clinical trial quality and oversight methodologies.

Main Methods:

• Consultation of documents from regulatory bodies including the Food and Drug Administration (FDA), European Medicines Association (EMA), and International Council for Harmonization (ICH).
• Decomposition of the issue into key components: monitoring gaps, oversight costs, and validation/effectiveness of testing methods.

Main Results:

• Identified significant gaps in the availability of detailed clinical trial quality information.
• Highlighted the lack of empirical evidence supporting the effectiveness of traditional oversight methods like SDV.
• Underscored the need for standardized validation and effectiveness testing of monitoring techniques.

Conclusions:

• Recommend the development of reference datasets with defined errors for clinical trials, analogous to analytic test standards.
• Advocate for systematic testing of monitoring methods using these datasets, reporting sensitivity, specificity, and predictive values.
• Urge the publication of clinical trial quality details, including major deviations, in primary publications to enhance scientific scrutiny.